Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study

Salyka Sengsayadeth; Myriam Labopin; Ariane Boumendil; Jürgen Finke; Arnold Ganser; Matthias Stelljes; Gerhard Ehninger; Dietrich Beelen; Dietger Niederwieser; Didier Blaise; Peter Dreger; Ghulam Mufti; Patrice Chevallier; Audrey Mailhol; Katie S. Gatwood; Norbert Gorin; Jordi Esteve; Fabio Ciceri; Frederic Baron; Christoph Schmid; Sebastian Giebel; Mohamad Mohty; Bipin N. Savani; Arnon Nagler

doi:10.1016/j.bbmt.2018.04.008

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study

Salyka Sengsayadeth, Myriam Labopin, Ariane Boumendil, Jürgen Finke, Arnold Ganser, Matthias Stelljes, Gerhard Ehninger, Dietrich Beelen, Dietger Niederwieser, Didier Blaise, Peter Dreger, Ghulam Mufti, Patrice Chevallier, Audrey Mailhol, Katie S. Gatwood^*, Norbert Gorin, Jordi Esteve, Fabio Ciceri, Frederic Baron, Christoph SchmidSebastian Giebel, Mohamad Mohty, Bipin N. Savani, Arnon Nagler

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

48 Citations (Scopus)

Abstract

Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared with de novo AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell transplantation (HCT); thus, this large systemic analysis of the European Society for Blood and Bone Marrow Transplantation registry was performed. This study included 4997 patients with sAML who received HCT from 2000 to 2016. In univariate analysis the 2-year cumulative incidence of chronic graft-versus-host disease (GVHD), relapse, and nonrelapse mortality (NRM) were 33.5% (95% confidence interval [CI], 32% to 34.9%), 33.7% (95% CI, 32.3% to 35.1%), and 27.5% (95% CI, 26.1% to 28.7%), respectively. Overall survival (OS), leukemia-free survival (LFS), and GVHD-free, relapse-free survival (GRFS) at 2 years were 44.5% (95% CI, 43% to 46%), 38.8% (95% CI, 37.4% to 40.3%), and 27.2% (95% CI, 25.9% to 28.6%), respectively. In multivariate analysis, patients receiving myeloablative regimens had decreased relapse (hazard ratio,.859; 95% CI,.761 to.97; P =.01), higher NRM (hazard ratio, 1.175; 95% CI, 1.03 to 1.341; P =.02), and no differences in OS, LFS, and GRFS compared with patients receiving reduced-intensity conditioning regimens. Active disease, adverse cytogenetics, older age, Karnofsky performance status (≤80%), ex vivo T cell depletion, other malignant hematologic diseases, and patient cytomegalovirus seropositivity were associated with inferior OS and LFS. These variables should be considered in patients with sAML in need of HCT, and further study regarding the impact of conditioning regimens on relapse is needed.

Original language	English
Pages (from-to)	1406-1414
Number of pages	9
Journal	BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume	24
Issue number	7
DOIs	https://doi.org/10.1016/j.bbmt.2018.04.008
Publication status	Published - 1 Jul 2018

Keywords

Acute myeloid leukemia
Allogeneic stem cell transplantation
Antileukemic effect
Conditioning
Secondary
Toxicity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bbmt.2018.04.008

Cite this

Sengsayadeth, S., Labopin, M., Boumendil, A., Finke, J., Ganser, A., Stelljes, M., Ehninger, G., Beelen, D., Niederwieser, D., Blaise, D., Dreger, P., Mufti, G., Chevallier, P., Mailhol, A., Gatwood, K. S., Gorin, N., Esteve, J., Ciceri, F., Baron, F., ... Nagler, A. (2018). Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(7), 1406-1414. https://doi.org/10.1016/j.bbmt.2018.04.008

@article{e2224ecc9feb43b99b40f4b65d95f58b,

title = "Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study",

abstract = "Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared with de novo AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell transplantation (HCT); thus, this large systemic analysis of the European Society for Blood and Bone Marrow Transplantation registry was performed. This study included 4997 patients with sAML who received HCT from 2000 to 2016. In univariate analysis the 2-year cumulative incidence of chronic graft-versus-host disease (GVHD), relapse, and nonrelapse mortality (NRM) were 33.5% (95% confidence interval [CI], 32% to 34.9%), 33.7% (95% CI, 32.3% to 35.1%), and 27.5% (95% CI, 26.1% to 28.7%), respectively. Overall survival (OS), leukemia-free survival (LFS), and GVHD-free, relapse-free survival (GRFS) at 2 years were 44.5% (95% CI, 43% to 46%), 38.8% (95% CI, 37.4% to 40.3%), and 27.2% (95% CI, 25.9% to 28.6%), respectively. In multivariate analysis, patients receiving myeloablative regimens had decreased relapse (hazard ratio,.859; 95% CI,.761 to.97; P =.01), higher NRM (hazard ratio, 1.175; 95% CI, 1.03 to 1.341; P =.02), and no differences in OS, LFS, and GRFS compared with patients receiving reduced-intensity conditioning regimens. Active disease, adverse cytogenetics, older age, Karnofsky performance status (≤80%), ex vivo T cell depletion, other malignant hematologic diseases, and patient cytomegalovirus seropositivity were associated with inferior OS and LFS. These variables should be considered in patients with sAML in need of HCT, and further study regarding the impact of conditioning regimens on relapse is needed.",

keywords = "Acute myeloid leukemia, Allogeneic stem cell transplantation, Antileukemic effect, Conditioning, Secondary, Toxicity",

author = "Salyka Sengsayadeth and Myriam Labopin and Ariane Boumendil and J{\"u}rgen Finke and Arnold Ganser and Matthias Stelljes and Gerhard Ehninger and Dietrich Beelen and Dietger Niederwieser and Didier Blaise and Peter Dreger and Ghulam Mufti and Patrice Chevallier and Audrey Mailhol and Gatwood, {Katie S.} and Norbert Gorin and Jordi Esteve and Fabio Ciceri and Frederic Baron and Christoph Schmid and Sebastian Giebel and Mohamad Mohty and Savani, {Bipin N.} and Arnon Nagler",

year = "2018",

month = jul,

day = "1",

doi = "10.1016/j.bbmt.2018.04.008",

language = "English",

volume = "24",

pages = "1406--1414",

journal = "BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "7",

}

Sengsayadeth, S, Labopin, M, Boumendil, A, Finke, J, Ganser, A, Stelljes, M, Ehninger, G, Beelen, D, Niederwieser, D, Blaise, D, Dreger, P, Mufti, G, Chevallier, P, Mailhol, A, Gatwood, KS, Gorin, N, Esteve, J, Ciceri, F, Baron, F, Schmid, C, Giebel, S, Mohty, M, Savani, BN & Nagler, A 2018, 'Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study', BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 24, no. 7, pp. 1406-1414. https://doi.org/10.1016/j.bbmt.2018.04.008

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. / Sengsayadeth, Salyka; Labopin, Myriam; Boumendil, Ariane et al.
In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol. 24, No. 7, 01.07.2018, p. 1406-1414.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Transplant Outcomes for Secondary Acute Myeloid Leukemia

T2 - Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study

AU - Sengsayadeth, Salyka

AU - Labopin, Myriam

AU - Boumendil, Ariane

AU - Finke, Jürgen

AU - Ganser, Arnold

AU - Stelljes, Matthias

AU - Ehninger, Gerhard

AU - Beelen, Dietrich

AU - Niederwieser, Dietger

AU - Blaise, Didier

AU - Dreger, Peter

AU - Mufti, Ghulam

AU - Chevallier, Patrice

AU - Mailhol, Audrey

AU - Gatwood, Katie S.

AU - Gorin, Norbert

AU - Esteve, Jordi

AU - Ciceri, Fabio

AU - Baron, Frederic

AU - Schmid, Christoph

AU - Giebel, Sebastian

AU - Mohty, Mohamad

AU - Savani, Bipin N.

AU - Nagler, Arnon

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared with de novo AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell transplantation (HCT); thus, this large systemic analysis of the European Society for Blood and Bone Marrow Transplantation registry was performed. This study included 4997 patients with sAML who received HCT from 2000 to 2016. In univariate analysis the 2-year cumulative incidence of chronic graft-versus-host disease (GVHD), relapse, and nonrelapse mortality (NRM) were 33.5% (95% confidence interval [CI], 32% to 34.9%), 33.7% (95% CI, 32.3% to 35.1%), and 27.5% (95% CI, 26.1% to 28.7%), respectively. Overall survival (OS), leukemia-free survival (LFS), and GVHD-free, relapse-free survival (GRFS) at 2 years were 44.5% (95% CI, 43% to 46%), 38.8% (95% CI, 37.4% to 40.3%), and 27.2% (95% CI, 25.9% to 28.6%), respectively. In multivariate analysis, patients receiving myeloablative regimens had decreased relapse (hazard ratio,.859; 95% CI,.761 to.97; P =.01), higher NRM (hazard ratio, 1.175; 95% CI, 1.03 to 1.341; P =.02), and no differences in OS, LFS, and GRFS compared with patients receiving reduced-intensity conditioning regimens. Active disease, adverse cytogenetics, older age, Karnofsky performance status (≤80%), ex vivo T cell depletion, other malignant hematologic diseases, and patient cytomegalovirus seropositivity were associated with inferior OS and LFS. These variables should be considered in patients with sAML in need of HCT, and further study regarding the impact of conditioning regimens on relapse is needed.

AB - Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared with de novo AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell transplantation (HCT); thus, this large systemic analysis of the European Society for Blood and Bone Marrow Transplantation registry was performed. This study included 4997 patients with sAML who received HCT from 2000 to 2016. In univariate analysis the 2-year cumulative incidence of chronic graft-versus-host disease (GVHD), relapse, and nonrelapse mortality (NRM) were 33.5% (95% confidence interval [CI], 32% to 34.9%), 33.7% (95% CI, 32.3% to 35.1%), and 27.5% (95% CI, 26.1% to 28.7%), respectively. Overall survival (OS), leukemia-free survival (LFS), and GVHD-free, relapse-free survival (GRFS) at 2 years were 44.5% (95% CI, 43% to 46%), 38.8% (95% CI, 37.4% to 40.3%), and 27.2% (95% CI, 25.9% to 28.6%), respectively. In multivariate analysis, patients receiving myeloablative regimens had decreased relapse (hazard ratio,.859; 95% CI,.761 to.97; P =.01), higher NRM (hazard ratio, 1.175; 95% CI, 1.03 to 1.341; P =.02), and no differences in OS, LFS, and GRFS compared with patients receiving reduced-intensity conditioning regimens. Active disease, adverse cytogenetics, older age, Karnofsky performance status (≤80%), ex vivo T cell depletion, other malignant hematologic diseases, and patient cytomegalovirus seropositivity were associated with inferior OS and LFS. These variables should be considered in patients with sAML in need of HCT, and further study regarding the impact of conditioning regimens on relapse is needed.

KW - Acute myeloid leukemia

KW - Allogeneic stem cell transplantation

KW - Antileukemic effect

KW - Conditioning

KW - Secondary

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85047617861&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.04.008

DO - 10.1016/j.bbmt.2018.04.008

M3 - Article

AN - SCOPUS:85047617861

SN - 1083-8791

VL - 24

SP - 1406

EP - 1414

JO - BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

JF - BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

IS - 7

ER -

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this